Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.

Binita Kane; Stephen J Fowler; Rob Niven

doi:10.1177/1479972314562210

Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.

Binita Kane, Stephen J Fowler, Rob Niven

FBMH Faculty Office Administration (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.

Original language	English
Journal	Chronic Respiratory Disease
Volume	12
Issue number	1
DOIs	https://doi.org/10.1177/1479972314562210
Publication status	Published - Feb 2015

Keywords

Refractory
asthma
novel
therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1479972314562210

Cite this

@article{997cf268503047e2bba1a9dc16be2f55,

title = "Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.",

abstract = "A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.",

keywords = "Refractory, asthma, novel, therapy",

author = "Binita Kane and Fowler, {Stephen J} and Rob Niven",

year = "2015",

month = feb,

doi = "10.1177/1479972314562210",

language = "English",

volume = "12",

journal = "Chronic Respiratory Disease",

issn = "1479-9723",

publisher = "Sage Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.

AU - Kane, Binita

AU - Fowler, Stephen J

AU - Niven, Rob

PY - 2015/2

Y1 - 2015/2

N2 - A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.

AB - A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.

KW - Refractory

KW - asthma

KW - novel

KW - therapy

U2 - 10.1177/1479972314562210

DO - 10.1177/1479972314562210

M3 - Article

C2 - 25492977

SN - 1479-9723

VL - 12

JO - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

IS - 1

ER -

Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this